Canada’s Drug Agency has recommended BIMZELX (bimekizumab injection) for reimbursement with conditions for patients with moderate to severe hidradenitis suppurativa, marking an important step forward in addressing a historically under-recognized chronic inflammatory skin disease. The recommendation follows examination of clinical evidence and stakeholder input from patients and clinicians.
Hidradenitis suppurativa is a chronic, recurring, painful, and debilitating inflammatory skin disease estimated to affect approximately one percent of the population, with women and people of color disproportionately impacted. Characterized by recurring nodules, abscesses, and pus-discharging openings in sensitive areas like the armpits, groin, and buttocks, the condition can significantly reduce quality of life. People with moderate to severe HS experience substantial impacts on physical and mental wellbeing, quality of life, and ability to carry out daily activities. Delayed diagnosis, stigma, and limited treatment options remain additional challenges for those living with HS.
The positive recommendation is based on clinical evidence from the Phase III BE HEARD I and BE HEARD II randomized controlled trials. BIMZELX is indicated for adults with moderate to severe HS with an inadequate response to conventional systemic therapy. This marks the fifth indication for BIMZELX in Canada, joining previous approvals for moderate to severe plaque psoriasis, active psoriatic arthritis, active ankylosing spondylitis, and active non-radiographic axial spondyloarthritis.
BIMZELX works by reducing the activity of two cytokines called IL-17A and IL-17F, which are present at increased levels in hidradenitis suppurativa and other inflammatory diseases. The drug is a monoclonal antibody belonging to a group of medicines called interleukin inhibitors. Latoya Palmer, Founder of Hidradenitis & Me Support Group, said the recommendation “offers hope to Canadians living with HS, a condition that can significantly impact both physical and mental health,” while Dr. Irina Turchin called HS “one of the worst conditions we see in dermatology due to its overwhelming impact on quality of life.” UCB Canada will engage with public drug plans and private payers across Canada to support timely, equitable, and sustainable access to the medication for eligible patients across all provinces.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.biospace.com/press-releases/bimzelx-bimekizumab-injection-receives-positive-reimbursement-recommendation-from-canadas-drug-agency-for-hidradenitis-suppurativa